DE69215612D1 - Verzögerte Freigabe-Matrix für Arzneimittel - Google Patents

Verzögerte Freigabe-Matrix für Arzneimittel

Info

Publication number
DE69215612D1
DE69215612D1 DE69215612T DE69215612T DE69215612D1 DE 69215612 D1 DE69215612 D1 DE 69215612D1 DE 69215612 T DE69215612 T DE 69215612T DE 69215612 T DE69215612 T DE 69215612T DE 69215612 D1 DE69215612 D1 DE 69215612D1
Authority
DE
Germany
Prior art keywords
drugs
release matrix
matrix
delayed release
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69215612T
Other languages
English (en)
Other versions
DE69215612T2 (de
Inventor
Thinnayam N Krishnamurthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Publication of DE69215612D1 publication Critical patent/DE69215612D1/de
Application granted granted Critical
Publication of DE69215612T2 publication Critical patent/DE69215612T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/15—Suppositories
DE69215612T 1991-09-11 1992-04-15 Verzögerte Freigabe-Matrix für Arzneimittel Expired - Lifetime DE69215612T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/758,883 US5215758A (en) 1991-09-11 1991-09-11 Controlled release matrix suppository for pharmaceuticals

Publications (2)

Publication Number Publication Date
DE69215612D1 true DE69215612D1 (de) 1997-01-16
DE69215612T2 DE69215612T2 (de) 1997-05-15

Family

ID=25053475

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69215612T Expired - Lifetime DE69215612T2 (de) 1991-09-11 1992-04-15 Verzögerte Freigabe-Matrix für Arzneimittel
DE69230475T Expired - Lifetime DE69230475T2 (de) 1991-09-11 1992-04-15 Verzögerte Freigabe Matrix für Arzneimittel

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69230475T Expired - Lifetime DE69230475T2 (de) 1991-09-11 1992-04-15 Verzögerte Freigabe Matrix für Arzneimittel

Country Status (13)

Country Link
US (2) US5215758A (de)
EP (2) EP0531611B1 (de)
JP (2) JP3034125B2 (de)
KR (2) KR100203339B1 (de)
AT (2) ATE145820T1 (de)
AU (1) AU653048B2 (de)
CA (1) CA2065210C (de)
DE (2) DE69215612T2 (de)
DK (2) DK0698389T3 (de)
ES (2) ES2139798T3 (de)
GR (1) GR3022572T3 (de)
IL (2) IL101758A (de)
ZA (1) ZA923417B (de)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
EP0652745A1 (de) * 1992-07-31 1995-05-17 Daratech Pty. Ltd. Implantate mit kontrollierter freisetzung
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
IL119660A (en) 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5891471A (en) 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5843480A (en) 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5670163A (en) * 1994-06-20 1997-09-23 Kv Pharmaceuticals Company Long acting GI and esophageal protectant
US5554379A (en) * 1994-06-20 1996-09-10 Kv Pharmaceutical Company Long acting GI and esophageal protectant
US5554380A (en) * 1994-08-04 1996-09-10 Kv Pharmaceutical Company Bioadhesive pharmaceutical delivery system
KR960016882A (ko) * 1994-11-01 1996-06-17 강재헌 치주염치료를 위한 서방출형 생분해성 제제
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
KR970064596A (ko) * 1996-03-21 1997-10-13 이우용 직장투여용 치질치료제 조성물
GB9710767D0 (en) * 1996-06-26 1997-07-23 On Ninh Analgesic and anti-inflamatory compositions comprising domperidone and methods of using same
WO1998001117A1 (en) * 1996-07-08 1998-01-15 Edward Mendell Co., Inc. Sustained release matrix for high-dose insoluble drugs
US6656508B2 (en) 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
US5989571A (en) * 1997-07-23 1999-11-23 Millenium Pharmaceutical Technologies, Inc. Contact dermatitis pharmaceutical preparation with anti-histamine and anti-inflammatory
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
CN1204890C (zh) * 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
RU2241458C2 (ru) 1997-12-22 2004-12-10 Эро-Селтик, С.А. Комбинации агонист/антагонист опиоида
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
GB9816899D0 (en) 1998-08-05 1998-09-30 Boots Co Plc Therapeutic agents
ATE310531T1 (de) 1998-08-07 2005-12-15 Stabilisierte pharmazeutische zusammensetzungen von hedgehog-proteinen und deren verwendung
US6200590B1 (en) 1998-08-10 2001-03-13 Naphcare, Inc. Controlled, phased-release suppository and its method of production
US6368625B1 (en) 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
EP1117384A1 (de) * 1998-10-01 2001-07-25 Elan Pharma International Limited Nanopartikelformulierungen mit kontrollierter wirkstofffreisetzung
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US6225343B1 (en) * 1999-06-16 2001-05-01 Nastech Pharmaceutical Company, Inc. Compositions and methods comprising morphine gluconate
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
AU762291B2 (en) * 1999-09-30 2003-06-19 Penwest Pharmaceutical Co. Sustained release matrix systems for highly soluble drugs
JP2003522144A (ja) 2000-02-08 2003-07-22 ユーロ−セルティーク，エス．エイ． オピオイドアゴニストおよびアンタゴニストを含む制御放出組成物
EP1935421A1 (de) 2000-02-08 2008-06-25 Euro-Celtique S.A. Kontrolliert freigesetzte Zusammensetzungen mit einem Opioid-Agonisten und einem Opioid-Antagonisten
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US20050214327A1 (en) * 2000-06-02 2005-09-29 Allergan, Inc. Neurotoxin-containing suppositories and related methods
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US6720356B2 (en) * 2001-04-20 2004-04-13 Spencer Feldman Magnesium di-potassium EDTA complex and method of administration
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
EP2311460A1 (de) * 2001-07-06 2011-04-20 Endo Pharmaceuticals Inc. Kontrolliert freisetzende Formulierungen von Oxymorphon
SI1416842T1 (sl) * 2001-07-18 2009-06-30 Euro Celtique Sa Farmacevtske kombinacije oksikodona in naloksona
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
ES2326794T3 (es) 2001-08-06 2009-10-20 Euro-Celtique S.A. Formulaciones de agonistas opioides con antagonista liberable y secuestrado.
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
JP2005508939A (ja) * 2001-10-12 2005-04-07 エラン ファーマ インターナショナル，リミティド 即時放出および徐放特性を組み合わせて有する組成物
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US6585996B1 (en) 2002-03-13 2003-07-01 Westlake Laboratories, Inc. Lipid-soluble thiamine derivatives in the treatment of autism
ES2546010T3 (es) 2002-04-05 2015-09-17 Euro-Celtique S.A. Preparación farmacéutica que contiene oxicodona y naloxona
US20050020613A1 (en) * 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use
PT1551372T (pt) 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc Subunidade de sequestração e composições e métodos relacionados
EP1599187A4 (de) * 2002-11-26 2007-08-08 Univ Maryland Wässriges arzneistoffabgabesystem mit anhaltenderwirkstofffreigabe für stark wasserlösliche elektrolytika
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
WO2005020933A2 (en) * 2003-09-02 2005-03-10 University Of South Florida Nanoparticles for drug-delivery
SI1663229T1 (sl) 2003-09-25 2010-08-31 Euro Celtique Sa Farmacevtske kombinacije hidrokodona in naltreksona
US20060194826A1 (en) 2003-09-25 2006-08-31 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
TW201509943A (zh) 2004-03-30 2015-03-16 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
EP1604666A1 (de) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
HUE037643T2 (hu) 2004-06-12 2018-09-28 Collegium Pharmaceutical Inc Visszaélésre nem alkalmas gyógyszerkészítmények
US9308164B2 (en) * 2004-06-30 2016-04-12 Sovereign Pharmaceuticals, Llc Hyoscyamine dosage form
EP1702558A1 (de) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
US20070082050A1 (en) * 2005-05-31 2007-04-12 Cherukuri S R Modified release formulations of antihypertensive drugs
KR100730321B1 (ko) 2005-09-30 2007-06-19 한국콜마 주식회사 패치형태의 리프팅용 2제형 화장료 조성물과 이의 제조방법및 사용방법
SE530184C2 (sv) 2005-12-23 2008-03-18 Kjell Stenberg Bioadhesiv farmaceutisk filmkomposition innehållande lågviskösa alginater
CA2635337C (en) * 2005-12-30 2015-02-17 Nir Barak Device for treating the anal sphincter
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20070286884A1 (en) * 2006-06-13 2007-12-13 Xylos Corporation Implantable microbial cellulose materials for hard tissue repair and regeneration
PL2526932T3 (pl) 2006-06-19 2017-12-29 Alpharma Pharmaceuticals Llc Kompozycja farmaceutyczna
WO2008011596A2 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophilic abuse deterrent delivery system
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
AU2008346870A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
ES2635733T3 (es) * 2008-07-07 2017-10-04 Euro-Celtique S.A. Uso de antagonistas opioideos para tratar la retención urinaria
DK2349250T3 (en) * 2008-10-31 2017-07-03 Lipid Pharmaceuticals Ehf Fatty acids for use as a medicament
SG174286A1 (en) 2009-03-10 2011-10-28 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
WO2010146591A2 (en) 2009-06-18 2010-12-23 Rdd Pharma Ltd. Methods and devices for delivery of pharmaceutical agents within orifices of the body
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
WO2012012147A2 (en) 2010-06-30 2012-01-26 Victoria Link Ltd Methods and compositions for treatment of multiple sclerosis
ES2643291T3 (es) 2010-12-22 2017-11-22 Purdue Pharma L.P. Formas de dosificación de liberación controlada con cierre inviolable recubiertas
CA2822769C (en) 2010-12-23 2016-10-04 Purdue Pharma L.P. Tamper resistant solid oral dosage forms
WO2014013313A1 (en) 2012-07-16 2014-01-23 Rhodes Technologies Process for improved opioid synthesis
CN104507947B (zh) 2012-07-16 2017-06-27 罗德科技公司 用于改进的阿片样物质合成的方法
CN102823585B (zh) * 2012-08-28 2014-06-25 中国农业科学院农业环境与可持续发展研究所 一种水溶性农药缓控释制剂及其制备方法
KR101840526B1 (ko) 2013-02-05 2018-03-20 퍼듀 퍼머 엘피 내변조성 제약 제제
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
EP2970320B1 (de) 2013-03-15 2020-10-28 Johnson Matthey Public Limited Company Morphinsulfatmethanolsolvat, verfahren zur herstellung davon sowie zugehörige zusammensetzungen und verfahren zur behandlung von schmerzen
NZ716267A (en) 2013-07-23 2017-05-26 Euro Celtique Sa A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
EP3027622B8 (de) 2013-08-02 2019-06-12 Johnson Matthey Public Limited Company Verfahren zur herstellung von oxymorphon
JP2017502015A (ja) * 2013-12-20 2017-01-19 ディスファー・インターナショナル・ベー・フェー 乾燥注腸製品
MX2016009125A (es) 2014-01-15 2017-02-02 Rhodes Tech Proceso para la sintesis mejorada de oximorfona.
TWI546074B (zh) 2014-01-15 2016-08-21 羅德科技公司 改良之羥考酮合成方法
US9062063B1 (en) 2014-03-21 2015-06-23 Johnson Matthey Public Limited Company Forms of oxymorphone hydrochloride
US9918979B2 (en) 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
US9145420B1 (en) 2015-03-27 2015-09-29 Johnson Matthey Public Limited Company Crystalline forms of morphine sulfate
US10196355B2 (en) 2016-06-20 2019-02-05 Johnson Matthey Public Limited Company Forms of apremilast
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629393A (en) * 1969-09-11 1971-12-21 Nikken Chemicals Co Ltd Release-sustaining-tablet
US4717713A (en) * 1983-10-31 1988-01-05 Research Corporation Controlled release liquid pharmaceutical
JPH0684296B2 (ja) * 1987-12-21 1994-10-26 花王株式会社 多層坐剤
US5102666A (en) * 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
US5110605A (en) * 1990-08-21 1992-05-05 Oramed, Inc. Calcium polycarbophil-alginate controlled release composition and method

Also Published As

Publication number Publication date
DE69230475T2 (de) 2000-07-13
AU2107392A (en) 1993-03-18
JP3034125B2 (ja) 2000-04-17
DE69230475D1 (de) 2000-01-27
US5215758A (en) 1993-06-01
IL101758A (en) 1996-12-05
EP0698389B1 (de) 1999-12-22
IL101758A0 (en) 1992-12-30
DK0531611T3 (da) 1997-05-26
DE69215612T2 (de) 1997-05-15
US5508043A (en) 1996-04-16
GR3022572T3 (en) 1997-05-31
ZA923417B (en) 1993-01-27
JP2000136149A (ja) 2000-05-16
KR100225493B1 (en) 1999-10-15
EP0531611B1 (de) 1996-12-04
EP0698389A1 (de) 1996-02-28
ATE145820T1 (de) 1996-12-15
IL117356A (en) 2000-08-31
CA2065210C (en) 2000-08-29
AU653048B2 (en) 1994-09-15
ATE187887T1 (de) 2000-01-15
ES2139798T3 (es) 2000-02-16
EP0531611A1 (de) 1993-03-17
CA2065210A1 (en) 1993-03-12
DK0698389T3 (da) 2000-05-01
JP3624123B2 (ja) 2005-03-02
JPH05148159A (ja) 1993-06-15
KR100203339B1 (ko) 1999-06-15
IL117356A0 (en) 1996-07-23
ES2097826T3 (es) 1997-04-16
KR930005616A (ko) 1993-04-20

Similar Documents

Publication Publication Date Title
DE69215612D1 (de) Verzögerte Freigabe-Matrix für Arzneimittel
EA200100541A1 (ru) Фармацевтическая композиция с модифицированным высвобождением сенсибилизатора к инсулину и других антидиабетических агентов
KR870005637A (ko) 약물 데포
NO944470L (no) Tablettkjerner av ulöselige legemidler med umiddelbar frigivelse og med belegg med forlenget frigivelse
DK0729357T3 (da) Mikroindkapslede 1,2-benzazoler
DK0605484T3 (da) Peptider med væksthormonfrigørende aktivitet
ES2090714T3 (es) Matriz de vidrio de carbohidrato para la liberacion prolongada de un agente terapeutico.
HK1003978A1 (en) Composition for the treatment of schizophrenia
DK4481A (da) Hydroxyalkylstivelse som laegemiddelbaerer
SE8800025L (sv) Bioadhesiva farmaceutiska suppositoriepreparat
SE8703889L (sv) Farmaceutiska kompositioner med fordrojd frigoring
DE69232014D1 (de) Amethocain enthaltende Arzneimittel
SE8704240D0 (sv) Analgesic preparations
ATE102934T1 (de) Fluorierte flavon-essigsaeure.
KR880012518A (ko) 나프탈-아세트산 유도체를 함유하는 진통 및 소염제약 조성물
KR900016130A (ko) 2-피리딜메틸티오 유도체 및 궤양 치료제
KR870000071A (ko) 수의 운동을 개선하는 신규약제 조성물 및 그의 생산공정
MY110416A (en) Composition for the treatment of schizophrenia.
GB1454389A (en) Nasal decongestants nasal decongestants
FR2628422B1 (fr) Le sel de sodium monohydrate de la 1,2- diphenyl-3,5-dioxo-4-n-butylpyrazolidine (" phenylbutazone ") et sa preparation
GT197640950A (es) Composiciones de oxitetraciclina y su preparacion.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R071 Expiry of right

Ref document number: 531611

Country of ref document: EP